HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies

Journal of Virology

Volumn 90, Issue 15, 2016, Pages 6999-7006

  Ali, Ayub ^a   Kitchen, Scott G ^a   Chen, Irvin S Y ^a,b   Ng, Hwee L ^a   Zack, Jerome A ^a,b   Yang, Otto O ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AIDS HEALTHCARE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CHIMERIC ANTIGEN RECEPTOR 10E8; CHIMERIC ANTIGEN RECEPTOR 3BNC117; CHIMERIC ANTIGEN RECEPTOR PG9; CHIMERIC ANTIGEN RECEPTOR PGT126; CHIMERIC ANTIGEN RECEPTOR PGT128; CHIMERIC ANTIGEN RECEPTOR VRC01; CHIMERIC ANTIGEN RECEPTOR X5; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; VIRUS RECEPTOR;

ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; AMINO ACID SEQUENCE; HUMAN; IMMUNOLOGY; JURKAT CELL LINE; SEQUENCE HOMOLOGY; T LYMPHOCYTE; VIROLOGY;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; JURKAT CELLS; RECEPTORS, ANTIGEN; RECEPTORS, HIV; SEQUENCE HOMOLOGY, AMINO ACID; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES;

EID: 84982868474     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00805-16     Document Type: Article

References (30)

1. + T lymphocytes armed with universal T-cell receptors. Blood 84:2878-2889.
2. Yang OO, Tran AC, Kalams SA, Johnson RP, Roberts MR, Walker BD. 1997. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci USA 94:11478-11483. http://dx.doi.org/10.1073/pnas.94.21.11478.
3. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA, Pennathur-Das R, Hege KM. 2000. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4([H11001]) and CD8( ) T cells in human immunodeficiency virus-infected subjects. Blood 96:785-793.
4. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM. 2002. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 5:788-797. http://dx.doi.org/10.1006/mthe.2002.0611.
5. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH. 2012. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4:132ra53. http://dx.doi.org/10.1126/scitranslmed.3003761.
6. Johnston SH, Lobritz MA, Nguyen S, Lassen K, Delair S, Posta F, Bryson YJ, Arts EJ, Chou T, Lee B. 2009. A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol 83:11016-11026. http://dx.doi.org/10.1128/JVI.01242-09.
7. Salter RD, Howell DN, Cresswell P. 1985. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21:235-246. http://dx.doi.org/10.1007/BF00375376.
8. Salter RD, Cresswell P. 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J 5:943-949.
9. Bennett MS, Ng HL, Dagarag M, Ali A, Yang OO. 2007. Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J Virol 81:4973-4980. http://dx.doi.org/10.1128/JVI.02362-06.
10. Yang OO, Kalams SA, Rosenzweig M, Trocha A, Jones N, Koziel M, Walker BD, Johnson RP. 1996. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol 70: 5799-5806.
11. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 71:3120-3128.
12. Bennett MS, Joseph A, Ng HL, Goldstein H, Yang OO. 2010. Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes. AIDS 24:2619-2628. http://dx.doi.org/10.1097/QAD.0b013e32833f7b22.
13. Wong JT, Colvin RB. 1987. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J Immunol 139:1369-1374.
14. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:406-412. http://dx.doi.org/10.1038/nature11544.
15. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637. http://dx.doi.org/10.1126/science.1207227.
16. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. http://dx.doi.org/10.1126/science.1178746.
17. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470. http://dx.doi.org/10.1038/nature10373.
18. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861. http://dx.doi.org/10.1126/science.1187659.
19. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS. 2002. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci USA 99:6913-6918. http://dx.doi.org/10.1073/pnas.102562599.
20. Severino ME, Sarkis PT, Walker BD, Yang OO. 2003. Chimeric immune receptor T cells bypass class I requirements and recognize multiple cell types relevant in HIV-1 infection. Virology 306:371-375. http://dx.doi.org/10.1016/S0042-6822(02)00055-7.
21. Ali A, Jamieson BD, Yang OO. 2003. Half-genome human immunodeficiency virus type 1 constructs for rapid production of reporter viruses. J Virol Methods 110:137-142. http://dx.doi.org/10.1016/S0166-0934(03)00110-1.
22. Adnan S, Balamurugan A, Trocha A, Bennett MS, Ng HL, Ali A, Brander C, Yang OO. 2006. Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood 108:3414-3419. http://dx.doi.org/10.1182/blood-2006-06-030668.
23. Bennett MS, Ng HL, Ali A, Yang OO. 2008. Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade anti-viral activity. J Infect Dis 197:390-397. http://dx.doi.org/10.1086/525281.
24. Chen DY, Balamurugan A, Ng HL, Yang OO. 2011. Antiviral activity of human immunodeficiency virus type 1 Gag-specific cytotoxic T lymphocyte targeting is not necessarily intrinsically superior to envelope targeting. J Virol 85:2474-2478. http://dx.doi.org/10.1128/JVI.01726-10.
25. Oren R, Hod-Marco M, Haus-Cohen M, Thomas S, Blat D, Duvshani N, Denkberg G, Elbaz Y, Benchetrit F, Eshhar Z, Stauss H, Reiter Y. 31 October 2014. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. J Immunol http://dx.doi.org/10.4049/jimmunol.1301769.
26. Webb NE, Montefiori DC, Lee B. 2015. Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies. Nat Commun 6:8443. http://dx.doi.org/10.1038/ncomms9443.
27. Gonzalez N, Alvarez A, Alcami J. 2010. Broadly neutralizing antibodies and their significance for HIV-1 vaccines. Curr HIV Res 8:602-612. http://dx.doi.org/10.2174/157016210794088236.
28. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, Lapedes A, Bhattacharya T, Migueles SA, Wyatt RT, Korber BT, Mascola JR, Connors M. 2010. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 84:1631-1636. http://dx.doi.org/10.1128/JVI.01482-09.
29. Sajadi MM, Guan Y, DeVico AL, Seaman MS, Hossain M, Lewis GK, Redfield RR. 2011. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr 57:9-15. http://dx.doi.org/10.1097/QAI.0b013e3182100c1b.
30. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83:757-769. http://dx.doi.org/10.1128/JVI.02036-08.